Biologic regulatory filing citing a Nature Communications paper — Metagenomi Therapeutics, 2025-01-16
Metagenomi TherapeuticsMetagenomi TherapeuticsNASDAQ MGX
Filings SEC · Quote Google cited a paper published in Nature CommunicationsNature Communications
Journal · Website as the basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange CommissionU.S. Securities and Exchange Commission
Regulator · Website. The company read the way it wrote the paper and the actual scope of the paper in order. The stock price movement for one month after the filing was compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.
The disclosure is written in the press release as follows:
When a U.S.-listed company has something to inform its shareholders, the report filed with the Securities and Exchange Commission is called 8-K. The item numbers of the document filed by Metagenomi Therapeutics on 2025-01-16 were 5.02 Officer and Director Changes · 7.01 Reg FD Disclosure · 9.01 Financial Statements and Exhibits. The company cited a paper published in Nature Communications in the press release attached to it. If the sentence citing the paper is translated verbatim, it reads as follows.
The press release did not automatically identify the sentence citing the paper. Check the original link. Do not substitute with another paragraph.
What the reader first sees is where the company placed the paper in the press release. Next is determining whether the paper supports the company's entire claim or only part of it. To answer the latter question, one must read the full paper. This article, having read only the abstract, cannot answer that.
The scope of the paper mentioned in the abstract is limited to this.
The paper's title is DNA targeting by compact Cas9d and its resurrected ancestor and it was published in Nature Communications on 2025-01-07. The authors are affiliated with The University of Texas at Austin · Institute of Science and Technology Austria · Livestrong Foundation. The summary at the beginning of the paper is called abstract. This article read only up to there. This paragraph was rewritten by a person after filtering a draft written by a machine by numerical comparison, so it is of a different grade than a full reading of the original.
This study captured the structure of Cas9d, a very small CRISPR protein used in gene editing, in various states using cryo-electron microscopy. The process of this 747-amino-acid protein finding DNA occurs in stages. It showed that shape changes in one region act as a switch. The folded guide RNA served as a scaffold holding small, flexible protein fragments, and cutting the guide RNA by a quarter still left functionality within the cell. Since this is a structural and cell experiment, whether it can be used for treatment is outside the scope of this paper.
The sections and appendices remain where the abstract does not answer. This text, which does not go there, leaves blanks as blanks. Readers compare the two citations above to determine which sentence in the abstract corresponds to the excerpt cited by the company.
One month later, the stock price was within the middle half of the sample.
The remaining return after subtracting the portion attributable to movement with the overall market is called excess return. Dates are recorded as trading days, counting only days when the stock market is open. In calendar terms, 20 trading days amount to about a month. The excess return for the day of the regulatory filing and the following month is presented in the table below.
| Period | Excess return relative to the market | Meaning |
|---|---|---|
| Five trading days before the filing | −14.1% | The extent to which it had already moved before the filing |
| On the filing day | −1.2% | The filing day or the first trading day following |
| +1~+5 trading days cumulative | +4.5% | One week |
| +1~+20 trading days cumulative | −5.0% | One month |
A bundle of past cases of the same type is called a sample. The position counted from the bottom is expressed as a percentile. The one-month excess return of −5.0% in this case is within the bottom 54% of the 142 cases in the sample, placing it in the lower half.
| Sample scale (20 trading days) | Tenth from the bottom | Fourth from the bottom | Median | Top 25% | top 10% | this case |
|---|---|---|---|---|---|---|
| excess return | −31.9% | −20.1% | −7.4% | +5.5% | +19.5% | −5.0% |
Half of the sample falls between the two central marks in the table. One checks from the table whether this case falls inside or outside. The sample collects cases where U.S. listed companies wrote papers in 8-K filings over the past ten years. The company itself is excluded from the sample. The numbers written here are past facts, not rules to apply to future cases.
After the regulatory filing, the company issued such documents
After the disclosure date, the company filed three 8-Ks. Here are only the item numbers. In 8-Ks without titles, the item numbers indicate the type of content. Whether it was an earnings release or a contract can be determined by the number. To learn what exactly happened, read the original text at each link.
- 2025-03-17 8-K Items 1.01,9.01 — Material contract execution · Financial statements · Exhibits
- 2025-03-17 8-K Items 2.02,7.01,9.01 — Earnings release · Reg FD disclosure · Financial statements · Exhibits
- 2025-05-13 8-K Items 2.02,7.01,9.01 — Earnings release · Reg FD disclosure · Financial statements · Exhibits
What this article did not answer
This article, based only on abstracts, cannot answer what method the paper used, what it demonstrated, or to what extent. The number of citations the company's paper has received afterward can be verified again using the citation count from OpenAlexOpenAlex
Data source · Website. The next thing to check is whether the company's next 8-K again cites the same paper.
Glossary
- 8-K
- A spontaneous report submitted to the Securities and Exchange Commission when a U.S. listed company has something to inform its shareholders. The type is indicated by item numbers such as earnings, contracts, and executive changes. All events in this article come from this document.
- Excess return
- The remainder obtained by subtracting the market's overall return from the stock's return. It is used to observe the company's unique movement after removing the portion attributable to the market's collective rise or fall.
- Trading day
- A count of days when the stock market is open. Weekends and holidays are excluded, so 20 trading days correspond to roughly one calendar month.
- Sample and percentile
- A bundle of past cases of the same type is a sample, and the position from the bottom within it is expressed as a percentile. A percentile of 10 means that nine out of ten cases performed better than this case.
- Abstract
- A summary appearing at the beginning of a paper. The author writes in a few sentences what was done, how it was done, and what results were obtained. Without reading the full text, one cannot know the details and limitations of the methods.